Emergent BioSolutions Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 58/100
What the filing says
Emergent BioSolutions cut FY2026 revenue guidance to $645–$675M (from $720–$760M), net loss to $(245)–$(225)M (from $(30)–$(10)M), and adjusted EBITDA to $130–$150M (from $155–$175M). The $191M impairment charge in Q2 and naloxone margin pressure (competitive generic/OTC entrants, aggressive pricing) drove revisions. Restructuring targets ~$40M annualized savings via 90-role workforce reduction, closure of two Maryland labs, and $6M office building sale. MCM segment remains strong ($168M Q2 revenue; $52.7M ACAM2000 contract, $64.5M BAT contract, $24M CYFENDUS award). Repurchased $75M debt principal; refinanced term loan to 2031.
Why this rating
Major guidance reduction (~10–15% revenue miss, ~130% worse net loss) and impairment mark material relative to $343M market cap. Naloxone headwinds are structural; restructuring is defensive. MCM strength partially offsets but does not reverse decline.
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.